1,226 research outputs found
Cómo editar el Laberinto de Fortuna de Juan de Mena?
No full textContains fulltext :
85496.pdf (Publisher’s version ) (Closed access
Optimization of ownership for the innovation economy of Russia.
No full textIn article the original author's concept on improvement of qualifiers of forms of the account of the property which the author uses as the precondition to re-structuring of toolkit of the sociologist for deep studying, improvement of a condition and development of economy of Russia at a new historical stage of development is stated. The rich actual material which has made base for theoretical constructions stated in article, the author has saved up, studying the big file of the scientific literature. Thanks to the popular statement which has been not overloaded with special terms, article can be useful not only to professional sociologists, philosophers and economists, but in general to all who is interested in those actual problems which are considered within the limits of corresponding sciences. The author will be deeply grateful to readers for responses and critical remarks for its work.Optimization of ownership, innovation economy
Current strategies in antifungal therapy for invasive aspergillosis in immunocompromised patients following hematopoietic stem cell transplantation
No full textShifting epidemiological trends in invasive fungal infections (IFI) have recently surfaced, with an increase in mould infections, which currently constitute the bulk of IFI. Many changes have contributed to this shift, including the widespread use of fluconazole prophylaxis, which successfully prevents Candida infections but not other IFI, as well as recent advances in hematopoietic stem cell transplant (HSCT) practices, with ever-growing immunosuppressive protocols and treatments for graft-versus-host disease. Allogeneic HSCT recipients are the subset of patients at the greatest risk, with an incidence of proven or probable IFI of 5-18percent and a crude mortality rate of 70-93percent. These alarming numbers have triggered unprecedented research into preventing these infections as well as identifying antifungal agents or combinations that would prove successful for treatment in such a high-risk population. In this review, the available evidence behind the use of various antifungal agents and their combinations as first-line, salvage, and prophylactic therapies for invasive aspergillosis (IA), with a special interest in HSCT recipients, is assessed. Various approaches for the management of such patients with IA in an era of growing antifungal resistance and development of new antifungal agents are also evaluated
In Search of Lost Meaning. Review of the Monograph by Kharayeva L.F., Kuchukova Z.A. “Gender and Ethnogender (on the Material of Kabardian Women’s Prose)”
No full textThe review offered to our readers is devoted to the study of the phenomenon of Kabardian women’s prose, presented in the monograph “Gender and Ethnogender” by L.F. Kharaeva and Z.A. Kuchukova. The author analyzes the monograph from the point of view of its structure, sequence of presentation, relevance to the topic and corpus of chosen literary texts. The undoubted value of the monograph recognizes its theoretical and practical significance, as well as an indisputable novelty. The author recommends this scientific research to be read by all who are interested in issues of gender and its ethnospecificity, gender literature, and the latest Kabardian literature
On the use of Spaceborne Remote Sensing for Archaeology: A case study on early iron production sites at the Jordan Valley
No full textThe purpose of this research was to investigate the surroundings of the Jordan Valley in Jordan with a large variety of spaceborne remote sensing data to examine the potential of this technique for the application of archaeology in general. The Jordan Valley is a region where many archaeological remains have been discovered, such as ancient settlements, old irrigation systems, and remains of early iron production. The used data sources includes multispectral (ASTER), hyperspectral (Hyperion), high-resolution (Quickbird), and radar data (ERS, Envisat and SIR-C). ASTER and Hyperion data are used to investigate the mineralogical content of the soil, whereas pan-sharpened Quickbird imagery is used to reveal the smallest structures in the landscape. Spectral field measurements are carried out as well for collecting groundtruth information. Radar (SAR) is used to map the terrain texture. Spaceborne remote sensing appears to be capable to map the known archaeological sites, showing its potential for the use in unexplored areas. However, the Jordan Valley itself is an area that is well known, and most archaeologically interesting features visible at the surface there are already documented, also detailed geological maps are available. No new discoveries therefore have been made.Aerospace Engineerin
Ceftaroline fosamil: drug profile and clinical data
No full text Several studies have shown that the rates of resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), hetero-VISA, and penicillin-resistant Streptococcus pneumoniae have witnessed a substantial global increase. Ceftaroline fosamil is the prodrug form of ceftaroline, a new cephalosporin active against resistant Gram-positive pathogens and common Gram-negative organisms that do not produce extended-spectrum-β-lactamases and do not express AmpC. Ceftaroline fosamil was found to be effective and well-tolerated for the treatment of complicated skin and skin-structure infections and community-acquired bacterial pneumonia compared with standard therapy. The drug has recently been granted US FDA approval for both indications. </jats:p
Tedizolid (TR-701): A new oxazolidinone with enhanced potency
No full textIntroduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. Areas covered: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics-pharmacodynamics, clinical efficacy and safety are all addressed. Expert opinion: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms. © 2012 Informa UK, Ltd.[Anonymous], 2001, AM J INFECT CONTROL, V29, P404; Betriu C, 2010, ANTIMICROB AGENTS CH, V54, P2212, DOI 10.1128-AAC.01653-09; Bien P., 2010, 50 INT C ANT AG CHEM; Brown SD, 2010, ANTIMICROB AGENTS CH, V54, P2063, DOI 10.1128-AAC.01569-09; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056-NEJMoa025025; Colak D, 2002, J ANTIMICROB CHEMOTH, V50, P397, DOI 10.1093-jac-dkf134; Colca JR, 2003, J BIOL CHEM, V278, P21972, DOI 10.1074-jbc.M302109200; Dreskin H, 2011, 51 INT C ANT AG CHEM; Falagas ME, 2006, J ANTIMICROB CHEMOTH, V58, P273, DOI 10.1093-jac-dkl219; Fluit AC, 2001, J CLIN MICROBIOL, V39, P3727, DOI 10.1128-JCM.39.10.3727-3732.2001; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056-NEJMoa043252; Gould IM, 2008, INT J ANTIMICROB AG, V31, P1, DOI 10.1016-S0924-8579(08)70002-5; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093-jac-40.1.135; Housman ST, 2011, 51 INT C ANT AG CHEM; Hsueh PR, 1999, INFECT CONT HOSP EP, V20, P828, DOI 10.1086-501592; Im WB, 2011, EUR J MED CHEM, V46, P1027, DOI 10.1016-j.ejmech.2011.01.014; Jacobson LM, 2009, PEDIATR INFECT DIS J, V28, P445, DOI 10.1097-INF.0b013e3181927891; Jones RN, 2009, J ANTIMICROB CHEMOTH, V63, P716, DOI 10.1093-jac-dkp021; Keel RA, 2011, 51 INT C ANT AG CHEM; Kirst HA, 1998, ANTIMICROB AGENTS CH, V42, P1303; Leach KL, 2007, MOL CELL, V26, P393, DOI 10.1016-j.molcel.2007.04.005; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056-NEJM198807213190307; Lemaire S, 2009, J ANTIMICROB CHEMOTH, V64, P1035, DOI 10.1093-jac-dkp267; Livermore DM, 2009, J ANTIMICROB CHEMOTH, V63, P713, DOI 10.1093-jac-dkp002; Locke JB, 2009, ANTIMICROB AGENTS CH, V53, P5265, DOI 10.1128-AAC.00871-09; Louie A, 2011, ANTIMICROB AGENTS CH, V55, P3453, DOI 10.1128-AAC.01565-10; Mangili A, 2005, CLIN INFECT DIS, V40, P1058, DOI 10.1086-428616; Moellering RC, 2003, ANN INTERN MED, V138, P135; Moise PA, 2000, INT J ANTIMICROB AG, V16, pS31; Munoz KA, 2011, 21 EUR C CLIN MICR I; Prasad JV, 2007, CURR OPIN MICROBIOL, V10, P454, DOI 10.1016-j.mib.2007.08.001; Prokocimer P, 2008, 48 INT C ANT AG CHEM; Prokocimer P, 2011, ANTIMICROB AGENTS CH, V55, P583, DOI 10.1128-AAC.00076-10; Ramsey AM, 2009, INFECT CONT HOSP EP, V30, P184, DOI 10.1086-593956; Rodriguez-Avial I, 2012, J ANTIMICROB CHEMOTH, V67, P167, DOI 10.1093-jac-dkr403; Sakoulas G, 2004, J CLIN MICROBIOL, V42, P2398, DOI 10.1128-JCM.42.6.2398-2402.2004; Garcia MS, 2010, JAMA-J AM MED ASSOC, V303, P2260, DOI 10.1001-jama.2010.757; Schaadt R, 2009, ANTIMICROB AGENTS CH, V53, P3236, DOI 10.1128-AAC.00228-09; Shaw KJ, 2008, ANTIMICROB AGENTS CH, V52, P4442, DOI 10.1128-AAC.00859-08; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173; van Hal SJ, 2011, EUR J CLIN MICROBIOL, V30, P603, DOI 10.1007-s10096-010-1128-3; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007-BF02026127; Woods CW, 2004, CLIN INFECT DIS, V38, P1188, DOI 10.1086-383027; Yamaki J, 2011, ANTIMICROB AGENTS CH, V55, P4432, DOI 10.1128-AAC.00122-11; Yum JH, 2010, ANTIMICROB AGENTS CH, V54, P5381, DOI 10.1128-AAC.00728-10; Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016-S1473-3099(05)70112-214171
Ceftaroline: A cephalosporin with expanded Gram-positive activity
No full textInfections caused by resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are now posing a major health risk for patients in hospital and community settings. There is a need to evaluate new antibiotics that would offer reliable clinical efficacy combined with a favorable safety profile for the treatment of such infections. Ceftaroline is a new member of the cephalosporin class of antibiotics with expanded activity against Gram-positive pathogens such as MRSA, vancomycin-intermediate S. aureus, vancomycin-resistant S. aureus and multidrug-resistant Streptococcus pneumoniae, while retaining good activity against common Gram-negative organisms. Phase II and III studies have shown ceftaroline to be an effective and well-tolerated treatment-tor complicated skin and skin-structure infections compared with standard therapy. Trials are ongoing in the treatment of community-acquired pneumonia. © 2009 Future Medicine.Andes D, 2006, ANTIMICROB AGENTS CH, V50, P1376, DOI 10.1128-AAC.50.4.1376-1383.2006; [Anonymous], 2006, M100S16 CLSI; BARRY PM, 2008, 48 ANN INT C ANT AG; Bo G, 2000, CLIN MICROBIOL INFEC, V6, P6; COREY GR, 2008, 48 ANN INT C ANT AG; Fenoll A, 2008, ANTIMICROB AGENTS CH, V52, P4209, DOI 10.1128-AAC.00712-08; Ge Y, 2006, 46 ANN INT C ANT AG; Ge Y, 2008, ANTIMICROB AGENTS CH, V52, P3398, DOI 10.1128-AAC.00149-08; Hinshaw RR, 2008, 48 ANN INT C ANT AG; Iizawa Yuji, 2004, Journal of Infection and Chemotherapy, V10, P146; Ishikawa T, 2003, BIOORGAN MED CHEM, V11, P2427, DOI 10.1016-S0968-0896(03)00126-3; JACQUELINE C, 2008, 48 ANN INT C ANT AG; JACQUELINE C, 2006, 46 ANN INT C ANT AG; Jacqueline C, 2007, ANTIMICROB AGENTS CH, V51, P3397, DOI 10.1128-AAC.01242-06; Kanafani ZA, 2006, ENFERM INFEC MICR CL, V24, P182, DOI 10.1157-13086552; Mariani PG, 2006, J ANTIMICROB CHEMOTH, V58, P481, DOI 10.1093-jac-dkl256; MOISE PA, 2000, ANTIMICROB AGENTS S1, V16, pS31; Mushtaq S, 2007, J ANTIMICROB CHEMOTH, V60, P300, DOI 10.1093-jac-dkm150; Riccobene T, 2008, 48 ANN INT C ANT AG; Sader HS, 2008, ANTIMICROB AGENTS CH, V52, P1153, DOI 10.1128-AAC.01351-07; Sader HS, 2005, ANTIMICROB AGENTS CH, V49, P3501, DOI 10.1128-AAC.49.8.3501-3512.2005; Sakoulas G, 2004, J CLIN MICROBIOL, V42, P2398, DOI 10.1128-JCM.42.6.2398-2402.2004; SARAVOLATZ LD, 2008, 48 ANN INT C ANT AG; SCHAADT RD, 2007, 47 ANN INT C ANT AG; Silverman JA, 2005, J INFECT DIS, V191, P2149, DOI 10.1086-430352; Talbot GH, 2007, ANTIMICROB AGENTS CH, V51, P3612, DOI 10.1128-AAC.00590-07; Tenover FC, 2007, CLIN INFECT DIS, V44, P1208, DOI 10.1086-513203; VIDAILLAC C, 2008, 48 ANN INT C ANT AG; Villegas-Estrada A, 2008, J AM CHEM SOC, V130, P9212, DOI 10.1021-ja8029448; Woods CW, 2004, CLIN INFECT DIS, V38, P1188, DOI 10.1086-383027; XIONG YQ, 2007, 47 ANN INT C ANT AG24181
Effect of stabilizing agent on the morphology and optical properties of silver nanoparticles
No full textOngoing deterioration of the nutritional status of Palestinian preschool children in Gaza under the Israeli siege
No full text- …
